What Cell and Gene Companies Need To Know About Leasing Space
Source: IPS-Integrated Project Services
By Herman F. Bozenhardt and Erich H. Bozenhardt
One of the most significant moves for a growing biotech or pharmaceutical company — sometimes considered as a graduation step — is the acquisition of property to conduct clinical trials and manufacture commercial products. The cost of such an acquisition is the single largest expense item on a biotech company’s books and the largest aspect its board of directors must underwrite. In the first installment of this two-part series, we will explore what considerations companies need to make before they decide what type of property to pursue.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
IPS-Integrated Project Services
This website uses cookies to ensure you get the best experience on our website. Learn more